Millrace Asset Group’s MaxCyte MXCT Stock Holding History

Millrace Asset Group’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-84,043	Closed	-$352K	–	83
2024 Q1	$352K	Buy	+84,043	New	+$395K	0.35%	63

Other funds holding MXCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $112M AUM 2.02% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Mudita Advisors London, United Kingdom $490M AUM 66.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Millrace Asset Group's MXCT Position: Q2 2024 in Review

Millrace Asset Group sold out of MaxCyte (MXCT) in Q2 2024, closing a stake of 84,043 shares — an estimated $352K sold.

Millrace Asset Group first reported a position in MXCT in Q1 2024 and held it in 1 quarter. The position peaked at $352K in Q1 2024. 114 funds tracked by Wall St. Rank hold MXCT as of Q2 2024.

Millrace Asset Group reported no remaining MaxCyte position as of Q2 2024 after selling out during the quarter.
Millrace Asset Group sold 84,043 MaxCyte shares in Q2 2024, an estimated $352K.
Millrace Asset Group first reported a position in MaxCyte in Q1 2024 and held it in 1 quarter.
Millrace Asset Group's MaxCyte position peaked at $352K in Q1 2024.
114 funds tracked by Wall St. Rank held MaxCyte as of Q2 2024.

Based on Millrace Asset Group's 13F filing for Q2 2024, filed 12 Aug 2024.